Good call Fangk, point taken.
A loss of NZ$1-3M NZ with cash reserves of NZ$30M is really not significant (in my view) with a 80%+ GM. In particular when they are spending so much on Selling and R&D which is more than the GM (extract below) resulting in negative earnings. So, question is will Sales hold up if they had less sales force or will they acheive more $/head sales with existing team with the same / new products? That would definitely turn the company profitable.
Besides that, I can't really find any reasons for negativity. Bit stumped on the price action for a long period of time now.
I dont really understand the BOT's and technicals but all I can see the volume / trade is very small and the company valuation is getting hammered as a result. And no broker / small-micro cap fund managerseems to cover this stock of recent times. Still buying but I am wondering what I am missing. Hmmmm.....
Sept 23 report
Normalised operating expenses
Selling and administrative expenses of NZ$27.5 million for the half-year were up 38%, compared to
H1 FY23 (NZ$19.9 million). On a constant currency basis, selling and administrative expenses were
up 36%, primarily reflecting increases to sales team headcount, increases in variable sales
compensation and increased clinical development activities.
Research and development expenses for the half-year of NZ$5.1 million were down 15%, compared
to H1 FY23, primarily reflecting the capitalisation of NZ$0.6 million in research in development costs
during H1 FY24 (H1 FY23 NZ$nil).
Come on finish 1.60 plus, page-448
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARX (ASX) to my watchlist
(20min delay)
|
|||||
Last
62.0¢ |
Change
0.010(1.64%) |
Mkt cap ! $213.4M |
Open | High | Low | Value | Volume |
61.5¢ | 62.0¢ | 61.0¢ | $147.9K | 241.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 61.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
62.0¢ | 92304 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 0.610 |
1 | 15 | 0.600 |
1 | 20000 | 0.590 |
1 | 1500 | 0.585 |
1 | 20000 | 0.580 |
Price($) | Vol. | No. |
---|---|---|
0.620 | 92304 | 2 |
0.630 | 8078 | 1 |
0.635 | 2112 | 2 |
0.645 | 40000 | 1 |
0.650 | 31799 | 2 |
Last trade - 16.10pm 12/06/2024 (20 minute delay) ? |
|
|||||
Last
61.0¢ |
  |
Change
0.010 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
60.5¢ | 62.0¢ | 60.0¢ | 169422 | ||
Last updated 15.02pm 12/06/2024 ? |
Featured News
ARX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
SPONSORED BY The Market Online